## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.0% below STRENGTH zone (3.0-6.0%); PEG 3.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($554.29)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Intuitive Surgical (ISRG) Stock After Hours on Dec. 23, 2025: Whatâ€™s Moving Shares and What to Watch Before the Dec. 24 Market Open**
- Source: ts2.tech | 20251224T033258 | Neutral | Relevance: 100%
- Intuitive Surgical (ISRG) stock closed slightly lower on December 23, 2025, and remained relatively flat in after-hours trading, reflecting a "quiet tape" typical before holiday periods. Investors are looking towards a shortened trading session on December 24, with lighter liquidity and the release of initial jobless claims as the primary watch points. Despite recent records in the broader market, focus for ISRG remains on earnings expectations for Q4 2025 and upcoming catalysts like the January 22, 2026 earnings call, as well as ongoing discussions around a minor FDA recall and expanded indications for the da Vinci SP system.

**2. Intuitive Surgical Earnings Preview: What to Expect**
- Source: Palmetto Grain Brokerage | 20251223T100808 | Somewhat-Bullish | Relevance: 100%
- Intuitive Surgical, a leader in robotic-assisted surgery, is expected to announce its fiscal Q4 2025 results soon, with analysts predicting an EPS of $1.83. Despite lagging behind the S&P 500 and Health Care Select Sector SPDR Fund in stock performance, and a recent downgrade from Citigroup, analysts maintain a "Moderate Buy" rating with a target price implying a 5.9% upside.

**3. Intuitive Surgical Earnings Preview: What to Expect**
- Source: FinancialContent | 20251223T044600 | Somewhat-Bullish | Relevance: 100%
- Intuitive Surgical, a leader in robotic-assisted surgery with a market cap of $205.2 billion, is expected to announce its fiscal Q4 2025 results soon. Analysts anticipate an EPS of $1.83, a 5.2% decline from the previous year, although the company has consistently beaten Wall Street estimates. Despite a recent downgrade by Citigroup, the consensus analyst rating for ISRG stock is a "Moderate Buy" with an average price target of $614.04.

**4. Baird Reaffirms Buy on Intuitive Surgical (ISRG) After New FDA Clearances**
- Source: Insider Monkey | 20251222T150840 | Bullish | Relevance: 100%
- Baird reaffirmed a Buy rating on Intuitive Surgical (ISRG) with a $655 price target, following the FDA's clearance of the da Vinci Single Port (SP) surgical system for three new procedures: inguinal hernia repair, cholecystectomy, and appendectomy. This expands the system's US indications, which already included urology and colorectal surgeries. The da Vinci SP enables complex operations through a single incision, and the company offers various instruments and services supporting these robotic systems globally.

**5. Baird Reaffirms Buy on Intuitive Surgical (ISRG) After New FDA Clearances**
- Source: Finviz | 20251222T150811 | Bullish | Relevance: 100%
- Baird has reaffirmed a Buy rating on Intuitive Surgical (ISRG) and maintained its $655 price target following new FDA clearances for its da Vinci Single Port (SP) surgical system. These clearances expand the system's indications to include inguinal hernia repair, cholecystectomy, and appendectomy, broadening its use beyond prior approvals. The da Vinci SP system allows surgeons to perform complex procedures through a single incision, with existing approvals in Europe, Japan, and Korea for a wider array of procedures.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $650 | $620 | +5% |
| 2025-12-17 | RBC Capital | $650 | $625 | +4% |
| 2025-12-11 | Citigroup | $635 | $650 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-12-11 | Citigroup | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($2.98M) |
| Sells | 13 ($5.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Insider selling cluster: $5.5M in recent transactions.
2. Valuation stretched: PEG 3.5x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.46 signals overvaluation risk, limited margin of safety. Forward P/E 59.2x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $206.9B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.46 |
| Forward P/E | 59.2 |
| Current P/E | 66.8 |
| YoY Growth | 12.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 2.0% to 1.0% (-1.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.0pp (needs >3.0% for momentum thesis). MRS_5 (-0.4%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.97% (CS: 86) | Neutral |
| RSI_14 | 60.7 | Neutral |
| MACD Histogram | 0.44 | Bullish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 1.055x | Above |
| vs SMA200 | 1.133x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $577.15
- **Stop Loss:** $554.29 (4.0% risk)
- **Target:** $600.01 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 52
- **Position Value:** $30,011.80
- **Portfolio %:** 30.01%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*